Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
| Project/Area Number |
23591763
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
SHINICHI Ota 滋賀医科大学, 医学部, 講師 (30583637)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SONODA Akinaga 滋賀医科大学, 医学部, 助教 (00571051)
新田 哲久 滋賀医科大学, 医学部, 講師 (40324587)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NITTA Norihisa 滋賀医科大学, 医学部, 講師 (40324587)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 血管新生阻害薬 / 抗腫瘍効果 / 画像評価 / 病理評価 |
|---|
| Research Abstract |
The anti-tumor effect of the angiogenesis inhibitors increased in the following order; bevacizumab, sorafenib, and thalidomide. The anti-tumor effects of the dual therapies except sorafenib and thalidomide were lower than those of the single therapies. However, the numbers of the dual therapies were not enough to consider them, therefore, more studies about the dual therapies were necessary. When the anti-tumor effect of the angiogenesis inhibitor was determined, the best and simple way was to measure the change of the tumor sizes before and after the therapy using CT. To measure the change of enhancement ratio using CT / DSA and to evaluate the necrosis ratio and the numbers of tumor vessels pathologically were unfitted for the response evaluation of the angiogenesis inhibitors.
|
Report
(4 results)
Research Products
(1 results)
